Oncotype DX test on unequivocally HER2-positive cases: Potential for harm

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 570-571

  Bhargava, Rohit ^a   Dabbs, David J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; TRASTUZUMAB;

BREAST CANCER; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FALSE NEGATIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; ONCOTYPE DX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT INDICATION;

BREAST NEOPLASMS; FEMALE; GUIDELINES AS TOPIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; NEOPLASM RECURRENCE, LOCAL; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84856822571     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1323     Document Type: Letter

References (4)

1. Bartlett JM, Starczynski J: Quantitative reverse transcriptase polymerase chain reaction and the Oncotype DX test for assessment of human epidermal growth factor receptor 2 status: Time to reflect again? J Clin Oncol 29:4219-4221, 2011
2. Dabbs DJ, Klein ME, Mohsin SK, et al: High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: An independent quality assurance study. J Clin Oncol 29:4279-4285, 2011
3. Baehner FL, Achacoso N, Maddala T, et al: Human epidermal growth factor receptor 2 assessment in a case-control study: Comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 28:4300-4306, 2010
4. Hammond ME, Hayes DF, Wolff AC: Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 29:e458, 2011